Current issue #9, 2017

Who is to benefit from a three-stage preference system

API manufacturing in Russia is Terra incognita. Until the Ministry of Industry and Trade published a draft document on a three-stage preference system for local manufacturers in state biddings, this topic had been raised infrequently. Presently, APIs are in the center of hot debates, the main question being “Who is primarily to benefit from this preference tool?” The opponents of this project assert that this move is too specific, and that it will be beneficial for a very small part of the market players. However, the entire government procurement market may be restructured.

[PharmVestnik # 09, 21/03/2017, p. 1, cont’d p. 8]

Crimea expands government purchases and shows good prospects

The Crimea officially re-unified with Russia three years ago; over that period, significant changes have occurred in the peninsula’s economy, including the pharma market. The government procurement of pharmaceuticals increased five-fold while becoming 100% Russia-oriented as no Ukrainian or any other imported drugs are being purchased any longer. The Crimean medical officials speak about the government procurement leaders as well prospects of this new Russian region in terms of the pharma market.

[PharmVestnik # 09, 21/03/2017, p. 2]

36.6 Group paid off a debt totaling 900 m RUB

In the economic recession period, the 36.6 Group’s shareholders followed a high-risk strategy acquiring troubled companies one after another. Their first acquisition was Pharmacy Chain 36.6 by itself that has changed the owners and merged with A.v.e; the next acquisition was Oriola and its pharmacies; still next was Pharmacy Chain A5. These acquisitions intrigued pharma market players as everyone wondered whether the new owners would be able to keep all assets they had acquired. However, it was the creditors who had the keenest interest as they had to get their money back. The payment obligation settlement process is underway. The biggest question is “Where the money comes from?”

[PharmVestnik # 09, 21/03/2017, p. 3]

Pharma companies were recommended to participate in educat...